Nutriband (NTRB) Expected to Announce Quarterly Earnings on Monday
by Teresa Graham · The Cerbat GemNutriband (NASDAQ:NTRB – Get Free Report) is expected to issue its results after the market closes on Monday, April 27th. Analysts expect the company to announce earnings of ($1.89) per share and revenue of $0.7650 million for the quarter.
Nutriband Trading Down 0.4%
NASDAQ:NTRB opened at $4.00 on Friday. Nutriband has a 1 year low of $3.42 and a 1 year high of $11.68. The stock has a market cap of $48.66 million, a price-to-earnings ratio of -1.30 and a beta of 1.92. The business has a fifty day moving average of $4.02 and a 200-day moving average of $4.87. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.35 and a current ratio of 7.52.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Nutriband stock. Vanguard Group Inc. increased its position in Nutriband Inc. (NASDAQ:NTRB – Free Report) by 1.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 202,738 shares of the company’s stock after buying an additional 3,111 shares during the quarter. Vanguard Group Inc. owned about 1.68% of Nutriband worth $1,429,000 at the end of the most recent reporting period. Institutional investors own 19.70% of the company’s stock.
About Nutriband
Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility.